J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
Full history for every metric is available with a Kvantra account
J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR bn | 17 | 20 | 24 | 31 | 34 | 39 | 41 | 41 |
| Operating profit | INR bn | 9 | 9 | ||||||
| Net profit | INR bn | 3 | 4 | 4 | 4 | 6 | 7 | 7 | 7 |
| EPS reported | INR | 44.45 | 44.60 | ||||||
| Operating cashflow per share | INR | 45.24 | 22.70 | ||||||
| Capex per share | INR | 5.30 | 2.92 | ||||||
| FCF per share | INR | 39.94 | 19.78 | ||||||
| Free cash flow | INR bn | 6 | 3 | ||||||
| Net debt | INR bn | -12 | -12 | ||||||
| Book value equity | INR bn | 42 | 42 | ||||||
| Book value per share | INR | 260.6 | 259.3 | ||||||
| Number of shares | m | 159.61 | 160.4 | ||||||
| DPS (TTM paid) | INR | - | 22.00 |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 46.61 | 54.09 | ||||||
| P/B LTM | x | 7.80 | 5.92 | ||||||
| P/S LTM | x | 9.03 | 5.93 | ||||||
| P/FCF LTM | x | 51.69 | 77.93 | ||||||
| EV/EBITDA LTM | x | 22.81 | 21.49 | ||||||
| EV/Sales LTM | x | 7.79 | 9.33 | ||||||
| Earnings Yield LTM | % | +2.15% | +1.85% | ||||||
| FCF Yield | % | +1.93% | +1.28% | ||||||
| Quality | |||||||||
| ROE | % | - | +18.67% | ||||||
| ROIC | % | +15.72% | +15.72% | ||||||
| Operating margin | % | +22.30% | +22.30% | ||||||
| Gross margin | % | +45.72% | +62.75% | ||||||
| FCF/Sales | % | +15.13% | +7.61% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +6.95% | +27.98% | ||||||
| Sales Growth YoY | % | +7.40% | +20.31% | ||||||
| Net Income Growth YoY | % | +7.56% | +28.38% | ||||||
| FCF Growth | % | -22.04% | -41.45% | ||||||
| Operating Profit Growth | % | +8.24% | +22.89% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.97% | +0.91% | ||||||
| Dividend Growth | % | -32.32% | +44.26% | ||||||
| Payout Ratio | % | - | +15.41% | ||||||
| FCF/Debt | x | 174.29 | 87.70 | ||||||
| Net Debt/EBITDA | x | -0.09 | -0.09 | ||||||
| EBIT/Net interest | x | 166.06 | 166.05 | ||||||
| Net debt/market cap | % | +0.01% | +0.01% | ||||||
| Net debt/Equity | x | -0.29 | -0.29 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
J. B. Chemicals & Pharmaceuticals Limited, established in 1976 and based in Mumbai, India, operates as a global pharmaceutical enterprise. The company is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical formulations, herbal treatments, and active pharmaceutical ingredients (APIs) for both domestic and international markets. Its API range features compounds such as diclofenac sodium, nifedipine, and ciprofloxacin. Beyond its own product lines, J. B. Chemicals provides comprehensive contract manufacturing services for various dosage forms, including tablets, injectables, gels, creams, capsules, and a specialized array of lozenges. Additionally, the company offers a suite of contrast media products essential for medical imaging, such as X-ray, MRI, and ultrasound. Their extensive portfolio addresses critical therapeutic areas, including but not limited to gastroenterology, anti-infectives, cardiovascular health, diabetes, respiratory conditions, pain management, and dermatology.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
J. B. Chemicals & Pharmaceuticals Limited, established in 1976 and based in Mumbai, India, operates as a global pharmaceutical enterprise. The company is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical formulations, herbal treatments, and active pharmaceutical ingredients (APIs) for both domestic and international markets. Its API range features compounds such as diclofenac sodium, nifedipine, and ciprofloxacin. Beyond its own product lines, J. B. Chemicals provides comprehensive contract manufacturing services for various dosage forms, including tablets, injectables, gels, creams, capsules, and a specialized array of lozenges. Additionally, the company offers a suite of contrast media products essential for medical imaging, such as X-ray, MRI, and ultrasound. Their extensive portfolio addresses critical therapeutic areas, including but not limited to gastroenterology, anti-infectives, cardiovascular health, diabetes, respiratory conditions, pain management, and dermatology.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free